Skip to content

Prospective study on clinical effect analysis of layer management in pregnancy to reduce urogenital infection rate

Prospective study on clinical effect analysis of layer management in pregnancy to reduce urogenital infection rate

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091674
Enrollment
Unknown
Registered
2024-11-01
Start date
2023-02-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asymptomatic bacteriuria during pregnancy

Interventions

Control group:Urine routine was monitored and signs of urinary tract irritation were observed according to the delivery procedures recommended by the national regulations and the Guidelines for Health
Observation group:Asymptomatic bacteriuria was managed, screened and treated

Sponsors

department of obstetrical, first affiliated hospital(army medical university)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women who have established a pregnancy care manual in the obstetrics clinic of our hospital; 2. The 11-12 weeks of pregnancy were evaluated as low-risk pregnant women according to the "Chongqing Pregnancy Risk Assessment Table" (revised version). 1) No abnormalities in general condition (BMI=29 =18.5, no genital tract malformations, pelvic stenosis, deformed pelvis, thoracic deformities, etc.), 2) No pregnancy co-infected diseases (no gonorrhea, genital warts, syphilis infection, HIV infection, hepatitis B virus infection and other genital tract infections, etc.), 3) No history of abnormal pregnancy and childbirth (2 times of spontaneous abortion, 2 times of induced abortion<, 2 times of preterm birth, no history <of stillbirth, stillbirth, congenital anomalies, dystocia, macrosomia, postpartum hemorrhage), 4) no history of special surgery (no history of laparoscopic uterine surgery, cardiac surgery, transplantation, assisted reproductive technology pregnancy), 5) No medical comorbidities (no systemic lupus erythematosus, kidney disease, heart disease, abnormal liver function, fatty liver, recurrent asthma, cor pulmonale, diabetes, thyroid disease, epilepsy, intellectual disability, mental illness, etc.) 6) No contact with suspected teratogenic drugs, physical and chemical factors and viral infections in the first trimester. 3. Participate in the study voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) scarred uterus; (2) Antibiotics or vaginal plugs have been used within two weeks; (3) Failure to understand the potential risks and benefits of the study, and failure to follow up and evaluate as required; (4) No capacity for civil conduct.

Design outcomes

Primary

MeasureTime frame
Genitourinary tract infection during pregnancy;

Secondary

MeasureTime frame
Preterm birth incidence;Incidence of abortion;Incidence of premature rupture of membranes;

Countries

China

Contacts

Public ContactLiu Heying

first affiliated hospital(army medical university)

117753908@qq.com+86 133 6822 1773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026